Sector News

AstraZeneca looks at selling U.S. campus to raise cash

August 26, 2016
Life sciences

AstraZeneca has raised billions of dollars in short-term cash by pawning off the rights to a growing list of its drugs that it says are not important for its long-term future.

Pfizer just this week agreed to pay $1.5 billion for AstraZeneca’s antibiotics portfolio. But the U.K. drugmaker is trying a new twist on its asset sales practice, putting its U.S. headquarters in Delaware up for sale with plans to lease it back to pick up some money.

The campus in Fairfax, DE, went on the market this week, Delawareonline reported. An AstraZeneca spokesperson told the news service that the drugmaker is looking at a number of options, including redeveloping the site.

“In order to fully explore this [redevelopment] possibility, AstraZeneca will be soliciting bids from real estate developers in the coming months and that requires us putting the site on the market for sale,” AstraZeneca spokeswoman Abigail Bozarth told the publication.

The move comes as AstraZeneca is in the midst of a variety of cost-cutting moves and as CEO Pascal Soriot works feverishly to build up the drugmaker’s top and bottom lines. The company in April announced it intended to make $1.1 billion in cost cuts and followed that up in May by whacking the jobs of about 1,600 U.S. contract sales reps.

The company, following an industry trend, also has been shedding products that fall outside the therapeutic fields in which it has the most potential, picking up much needed cash along the way.

Pfizer is buying 5 antibiotics, including the rights to two still under development. In June, AstraZeneca agreed to sell the U.S. rights to 7 drugs to South Africa’s Aspen Pharmacare for up to $770 million. That deal followed many others. It sold a partnership for $500 million to Eli Lilly on an Alzheimer’s drug, and also sold Movantik, its treatment for opioid-induced constipation to Japan’s Daiichi Sankyo, for another $200 million.

While it is unclear how much the real estate deal might bring, property experts told the publication that a sale for redeveloping the campus might actually yield a substantial return, given its location and how much underutilized space there is. AstraZeneca has actually taken several buildings down on the site, following an earlier round of cost-cutting and layoffs.

By Eric Palmer

Souce: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”